Since being included in the medical insurance scheme, Orelabrutinib has seen a substantial price reduction, leading to a marked decrease in out-of-pocket expenses for patients. According to the 2023 National Medical Insurance Catalog, the negotiated price of Orelabrutinib—a BTK inhibitor indicated for the treatment of B-cell lymphoma—ranges approximately from $500 to $600 per box. Prices vary slightly depending on specifications and regions, representing a price cut of about 50% to 60% compared with the original price. After medical insurance reimbursement, the annual treatment cost for patients can be reduced to tens of thousands of yuan, significantly alleviating their financial burden.
Key Information Notes
1. Price and Specifications
Orelabrutinib is typically available in specifications such as 30 mg × 30 tablets/box and 50 mg × 30 tablets/box. Prices differ by specification; please refer to the official pricing posted by hospitals or pharmacies for details.
The medical insurance reimbursement rate ranges from 50% to 80% on average, with some regions offering even higher rates. Specific rates are subject to variations in insurance types (e.g., urban and rural resident medical insurance, employee medical insurance) and local policies.
2. Reimbursement Criteria
Orelabrutinib is a prescription drug and must be used strictly as directed by a physician. Medical insurance reimbursement is generally restricted to specific indications, including relapsed/refractory mantle cell lymphoma and chronic lymphocytic leukemia.
Patients must purchase the drug through hospitals or designated channels and apply for reimbursement with a physician-issued prescription and diagnostic certificate.
3. Cost Calculation Example
Taking a daily dosage of 1 tablet (50 mg) as an example, approximately 12 boxes are required annually. Based on the post-insurance unit price of 4,000 yuan per box, the total annual cost amounts to about 48,000 yuan. With a 70% reimbursement rate, the patient’s out-of-pocket expense is around 14,400 yuan. The actual cost may be even lower in some cities that offer supplementary insurance or critical illness assistance programs.
4. Medical Consultation and Medication Guidance
Patients need to undergo regular re-examinations, including blood routine tests, liver and kidney function assessments, etc. Physicians will adjust the treatment regimen based on treatment efficacy and adverse reactions.
In case of severe adverse reactions such as infection or bleeding, the drug must be discontinued immediately and medical attention should be sought promptly.
Notes
Orelabrutinib is a nationally negotiated medical insurance drug, and the implementation timeline may vary slightly across regions. It is recommended to consult the local medical insurance bureau or hospital pharmacy for the most up-to-date pricing information.
Eligible patients may apply for charitable assistance programs to further reduce costs. For details, please consult the attending physician or relevant public welfare organizations.
The drug must be used under the guidance of a qualified physician. Do not adjust the dosage or discontinue the medication without authorization.
